2-Amino-5-Bromothiazole Hydrobromide

Product Name 2-Amino-5-Bromothiazole Hydrobromide
Alias 2-AMINO-5-BROMO-1,3-THIAZOLE HYDROBROMIDE
Einecs EINECS 226-189-1
Mininmum Order 1g
Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
Price Inquiry sales9@bouling-chem.com
Manufacturer Bouling Chemical Co., Limited
CONTACT NOW

In terms of specification, 2-Amino-5-Bromothiazole Hydrobromide is supplied with assay (≥98% by HPLC) and water content (≤0.5% by KF), making it suitable for pharmaceutical intermediate synthesis.

Specifications

HS Code	378847
Chemical Formula	C3H4Br2N2S
Molecular Weight	245.95
Appearance	Typically a solid (color may vary depending on purity)
Solubility	Soluble in some polar solvents like water to an extent
Melting Point	Data specific to this compound's hydrobromide form needed (estimation: relatively high due to ionic nature)
Purity	Can be produced in various purity levels (e.g., 95%, 98% etc. depending on manufacturing process)
Odor	Likely has a faint, characteristic odor related to thiazole compounds
Density	Data specific to this compound's hydrobromide form needed
Stability	Stable under normal conditions but may react with strong oxidizing agents

As an accredited 2-Amino-5-Bromothiazole Hydrobromide factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

Packing & Storage

Packing	100g of 2 - Amino - 5 - Bromothiazole Hydrobromide packaged in a sealed plastic bag.
Shipping	2 - Amino - 5 - Bromothiazole Hydrobromide is shipped in well - sealed containers, following strict chemical handling protocols. It's transported by carriers compliant with hazardous material regulations to ensure safe delivery.
Storage	2 - Amino - 5 - Bromothiazole Hydrobromide should be stored in a cool, dry place, away from direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contact with air, which could potentially cause degradation. Store it separately from incompatible substances, following proper chemical storage guidelines to ensure safety and maintain its chemical integrity.

Application of 2-Amino-5-Bromothiazole Hydrobromide

When a Bromo Substituent Enables Late-Stage Diversification

The use of 2‑amino‑5‑bromothiazole hydrobromide in pharmaceutical manufacturing is concentrated in convergent synthetic routes where the aryl bromide serves as a handle for palladium‑catalysed cross‑coupling. In a representative pilot‑plant campaign for a thiazole‑containing non‑nucleoside reverse‑transcriptase inhibitor, the hydrobromide salt is charged as a methanol‑wetted solid directly into a 2000 L glass‑lined reactor equipped with a retreat‑curve impeller and jacket temperature capability of −15 °C to 140 °C. Free‑basing is performed by adding 2.5 equivalents of aqueous sodium carbonate at 10–15 °C under a nitrogen sweep to prevent carbamate formation. The resulting free amine is extracted into tetrahydrofuran and subjected to Suzuki–Miyaura coupling with a boronic acid pinacol ester using Pd(OAc)₂ (0.5 mol%) and tricyclohexylphosphine (1.1 mol%) at 65–68 °C for 16 h. Conversion monitoring by HPLC (Zorbax SB‑C18, 250 × 4.6 mm, 5 μm, gradient acetonitrile/0.1% H₃PO₄) typically shows ≥ 97% product with ≤ 0.8% des‑bromo impurity. After aqueous work‑up and Darco‑G60 treatment, the coupled intermediate is crystallised from ethyl acetate/n‑heptane (1:4 v/v) to yield an off‑white solid that meets residual palladium specification ≤ 10 ppm as measured by ICP‑MS per USP <233>. The narrow processing window is dictated by exotherm onset at 70 °C; exceeding this threshold promotes debromination with hydrogenolysis on the Pd catalyst, generating the unsubstituted thiazole by‑product that co‑elutes in the next downstream step and cannot be purged by normal‑phase chromatography. Batch records from a 6‑campaign dataset reveal that moisture content in the THF extract exceeding 0.3% KF correlates with catalyst deactivation and requires a subsequent polish filtration through 0.5 μm polypropylene cartridge before coupling to restore turnover number above 1000. Where the target API falls under ICH Q7 requirements, the isolated intermediate must be tested against a panel of class‑2 residual solvents; the acceptance limits for dichloromethane (≤ 600 ppm) and 1,4‑dioxane (≤ 380 ppm) are validated by headspace GC‑FID in accordance with USP <467> method IV. Failure mode analysis from a commercial batch that exhibited polymorphic shift during drying underscored the need for vacuum drying at 40 °C (5–10 mbar) with a ramp rate not exceeding 2 °C/h to preserve Form I that provides acceptable filtration kinetics during final API isolation.

**Table 1** — Purity Profile Benchmarks Across Three Downstream Sectors (Representative Commercial Lot Analysis)
Parameter	Pharmaceutical Intermediate	Agrochemical Active	Research‑Grade Building Block	Test Method
Assay (anhydrous, solvent‑free basis)	≥ 98.5%	≥ 97.0%	≥ 95.0%	HPLC USP <621>
Water (Karl Fischer)	≤ 0.5%	≤ 0.8%	≤ 0.5%	KF coulometry USP <921> Method Ia
Residue on ignition	≤ 0.1%	≤ 0.2%	Not routinely reported	Gravimetric USP <281>
Palladium (Pd)	≤ 10 ppm	≤ 25 ppm	≤ 50 ppm	ICP‑MS USP <233>
Any single organic impurity	≤ 0.5%	≤ 1.0%	≤ 2.0%	HPLC area% Ph. Eur. 2.2.29
Bulk density (tapped)	0.35–0.55 g/mL	0.30–0.60 g/mL	Not controlled	ASTM D7481‑18

A Scaffold for Thiazole Carboxamides in Crop Protection

Discovery programmes targeting succinate dehydrogenase inhibitors (SDHIs) have positioned 2‑amino‑5‑bromothiazole hydrobromide as a strategic intermediate for the preparation of 5‑aryl‑substituted thiazole‑4‑carboxamide fungicides. Scale‑up runs conducted on a 500 L Hastelloy reactor train with an in‑line static mixer for acid quenching demonstrate that the bromine atom exhibits orthogonal reactivity to the amino group during magnesium‑halogen exchange. Treatment of the free amine with isopropylmagnesium chloride‑lithium chloride complex (1.1 eq, −20 °C, THF) generates a Grignard intermediate that is trapped with dialkyl oxalate to install the carboxamide precursor, while leaving the C‑5 bromine untouched for a subsequent iron‑catalysed cross‑coupling with aryl zinc reagents. This route avoids the catalytic hydrogenation step that would be incompatible with the bromine functionality and reduces the overall process mass intensity by 18% relative to the linear sequence. The downstream active ingredient, formulated as a 250 g/L suspension concentrate (SC) containing 12% w/w ethoxylated tristyrylphenol phosphate surfactant (CAS 90093‑37‑1), is subjected to accelerated storage stability testing per CIPAC MT 46.3 at 54 °C for 14 days; the specification demands ≤ 5% growth in particle size D₉₀ and ≤ 0.2% w/w settled residue after centrifugation at 2000 rpm. Environmental fate characterisation under EU 1107/2009 requires determination of the degradation half‑life in three soil types (loamy sand, silt loam, clay loam) using OECD 307 guidelines; the thiazole moiety typically exhibits DT₅₀ values between 12 and 45 days, and the bromine substituent retards hydrolytic cleavage at pH 7 (half‑life > 1 year in sterile buffer at 25 °C, OECD 111). During registration, the applicant must document that the technical grade intermediate, when processed under Good Laboratory Practice, contains no detectable mutagenic brominated dioxin‑like impurities above the analytical reporting threshold of 0.1 μg/kg (GC‑HRMS, EPA Method 8290A). A recurrent scale‑up issue involves the formation of a tarry by‑product during the quench step if the temperature rises above −5 °C; this tar binds to the Hastelloy surface and reduces heat transfer coefficient by 40%, necessitating a cleaning cycle with hot dimethyl sulfoxide that extends the batch turnaround time by 6 h.

In early‑stage medicinal chemistry laboratories, 2‑amino‑5‑bromothiazole hydrobromide is dispensed into 8‑mm screw‑cap vials in a glovebox with an atmosphere of < 10 ppm O₂ and < 5 ppm H₂O, pre‑dried under high vacuum (0.1 mbar) over phosphorus pentoxide to a water content of ≤ 0.2% KF. The material is a key input for parallel Buchwald–Hartwig amination libraries designed to probe adenosine A_2A receptor antagonists. A typical 96‑well plate protocol weighs 15 μmol (4.0 mg) of the hydrobromide salt per well, adds 18 μmol of amine together with 2.5 mol% Pd₂(dba)₃·CHCl₃ and 5.0 mol% BrettPhos, and runs in 250 μL anhydrous 1,4‑dioxane at 85 °C for 18 h on a heated orbital shaker. Reaction success, defined as LC‑MS (ESI+) product purity ≥ 90% at 254 nm, drops to 65% when the relative humidity inside the glovebox exceeds 8%, because water promotes protodebromination competing with oxidative addition. Plate cooling to −20 °C prior to uncapping prevents cross‑contamination by condensation, a failure mode documented during a high‑throughput synthesis campaign that resulted in 12% well‑to‑well false positives. The purified library compounds—recovered by preparative HPLC with mass‑directed fractionation on a Waters AutoPurification system—are screened at 10 μM in a radioligand binding assay ([³H]‑ZM241385), and SAR trends extracted from substituent‑dependent bromine retention reveal that C‑5 substitution exerts a 5‑fold impact on K_i relative to C‑2 substitution. Material that fails the research‑grade specification for residual palladium (50 ppm limit) is treated with QuadraSil^™ AP metal scavenger (100 mg per gram of crude) in dichloromethane for 2 h; this operation consistently lowers Pd to ≤ 5 ppm and is validated by quarterly spike‑recovery experiments against CRM solutions traceable to NIST SRM 3108.

Bridging the Gap Between Genomics and Fluorescence Microscopy

Synthesis of thiazole orange analogues for DNA intercalation and fluorescence labelling relies on the bromine at C‑5 as the sole point for alkylation during quaternisation of a pendent benzothiazole moiety. In a representative procedure adapted to a 20 L jacketed vessel, 2‑amino‑5‑bromothiazole hydrobromide is first N‑alkylated with 3‑bromopropyltrimethylammonium bromide (1.05 eq) in anhydrous dimethylacetamide using potassium carbonate (2.5 eq) at 110 °C for 14 h. The resulting quaternary intermediate is fused with 2‑methylthiobenzothiazole to install the asymmetric cyanine scaffold; the crude dye, after precipitation from isopropanol/ethyl acetate, is purified by reverse‑phase flash chromatography (Biotage® Sfär C18, 120 g column, gradient methanol/water + 0.1% trifluoroacetic acid) to remove non‑fluorescent precursors that quench quantum yield. Final product, supplied as a lyophilised solid with a purity of ≥ 99% by HPLC‑FLR (ex 488 nm/em 520 nm), is used to manufacture ready‑to‑use flow cytometry reagents that must comply with ISO 13485:2016 Clause 7.3.3 for design and development inputs. Critical quality attributes include absorbance ratio A₂₆₀/A₂₈₀ of the DNA‑dye complex (1.8–2.0), absence of PCR inhibitors detected through a qPCR amplification shift of ≤ 0.5 threshold cycles compared to a negative control (ISO 17822:2020), and sterility testing per USP <71> with incubation for 14 days in fluid thioglycollate medium. During industrial‑scale lyophilisation, pre‑freezing at −50 °C (0.5 °C/min ramp) under shelf‑screening low oxygen (≤ 2%) prevents methanolic ester formation that is observed when headspace oxygen exceeds 5%; this oxidative pathway generates a fluorescent impurity with emission shifted to 550 nm, compromising the multiplexing window in 4‑colour flow cytometry panels. Batch release testing employs a PTI QuantaMaster™ spectrofluorometer calibrated with rhodamine B quantum yield standard (QY 0.65 in ethanol) to verify product fluorescence intensity ≥ 90% of the reference lot. Residual solvent limits are set to ≤ 500 ppm for dimethylacetamide and ≤ 3000 ppm for isopropanol as per ICH Q3C Class 2 and Class 3 designations.

Metalworking fluid manufacturers incorporate 2‑amino‑5‑bromothiazole hydrobromide as a precursor to synthesise brominated thiazole antimicrobials that exhibit broad‑spectrum activity against Gram‑negative bacteria prevalent in sump environments. The active is generated in situ by condensation with phenyl isothiocyanate followed by bromine‑mediated cyclisation in a continuous‑flow tubular reactor (Corning® G1, 10 modules, residence time 120 s, 100 °C back‑pressure 5 bar) to minimise the accumulation of a shock‑sensitive by‑product identified as a dithiazole disulfide. A 15% w/w concentrate in diethylene glycol monobutyl ether is dosed into a semi‑synthetic metalworking fluid at 500–1500 ppm active on fluid volume; efficacy is evaluated by ASTM E2275‑19 weekly challenge tests wherein a mixed bacterial inoculum (Pseudomonas aeruginosa ATCC 9027, Klebsiella pneumoniae ATCC 13883, Enterobacter aerogenes ATCC 13048) is introduced at 10⁶ CFU/mL and viability is assessed by plate count after 48 h. Typical fluid formulations containing the biocide precursor maintain CFU counts ≤ 10² for 12 successive challenges, whereas control fluids exceed 10⁶ by week 4. The intact molecule is not directly added to fluids because the free hydrobromide salt hydrolyses at pH > 8.5 and liberates 2‑amino‑5‑hydroxythiazole, a species with 10‑fold lower activity; on‑site generation ensures that the turnover to the active thiazolothione occurs within the fluid matrix where the pH is buffered to 8.7–9.2 by triethanolamine. Aquatic toxicity data required for REACH registration of the generated active (EC number assigned upon notification) are summarised in Table 2. Compatibility screening with amine‑borate corrosion inhibitors must be performed prior to field deployment because the brominated thiazole forms a charge‑transfer complex with secondary amines that precipitates as a sticky red gum; this incompatibility can be mitigated by switching to a tolyltriazole‑based inhibitor system. Batch stability of the concentrate is monitored by ion chromatography for free bromide, with the acceptance criterion of ≤ 2.0% bromide relative to total bromine content to confirm that no thermal dehydrobromination has occurred during storage at 25 °C for 12 months.

**Table 2** — Acute Aquatic Toxicity Endpoints for the Thiazole‑Derived Biocide Active (86/548/EEC Data Set)
Test Guideline	Organism	Endpoint	Measured Value
OECD 201	Pseudokirchneriella subcapitata (algae)	ErC50 72 h	1.2 mg/L
OECD 202	Daphnia magna (water flea)	EC50 48 h (immobilisation)	0.95 mg/L
OECD 203	Oncorhynchus mykiss (rainbow trout)	LC50 96 h	2.3 mg/L
OECD 209	Activated sludge	EC50 3 h (respiration inhibition)	8.7 mg/L
OECD 301B	Ready biodegradability (CO₂ evolution)		18% in 28 d (not readily biodegradable)

Free Quote

Competitive 2-Amino-5-Bromothiazole Hydrobromide prices that fit your budget—flexible terms and customized quotes for every order.

For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

We will respond to you as soon as possible.

Tel: +8615651039172

Email: sales9@bouling-chem.com

Get Free Quote of Bouling Chemical Co., Limited

Flexible payment, competitive price, premium service - Inquire now!

Get A Free Quote Now

Certification & Compliance

2-Amino-5-Bromothiazole Hydrobromide is manufactured under an ISO 9001 quality system and complies with relevant regulatory requirements.
COA, SDS/MSDS, and related certificates are available upon request. For certificate requests or inquiries, contact: sales9@bouling-chem.com.

More Introduction

A crystalline salt, 2-Amino-5-bromothiazole hydrobromide functions primarily as a protected, non-hygroscopic form of the heterocyclic amine building block 2-amino-5-bromothiazole. The free base (CAS 3034-48-8) is susceptible to oxidative discoloration and atmospheric moisture uptake during storage; protonation with hydrobromic acid yields a stable, free-flowing powder with a defined melting point of 189–193 °C (decomposition), as measured by differential scanning calorimetry at 10 K·min⁻¹ under nitrogen. This salt is supplied in purity grades from 98.0% (industrial grade) to >99.5% (HPLC, λ = 254 nm) for advanced pharmaceutical intermediate applications. Residual bromide content, exclusive of the stoichiometric counterion, is controlled to <0.1% via argentometric titration, while the sulfated ash value remains below 0.05% for material meeting EP general monograph requirements for substances used in active pharmaceutical ingredient (API) synthesis.

Specifications and Lot-Release Testing Under ICH Q7A Frameworks

Routine lot analysis employs a reversed-phase C18 column (150 mm × 4.6 mm, 5 µm particle size) with a mobile phase of 0.1% trifluoroacetic acid in water/acetonitrile (85:15 v/v). The retention time of the 2-amino-5-bromothiazolium cation appears at approximately 6.2 min under isocratic flow of 1.0 mL·min⁻¹. Identity confirmation by ¹H NMR (DMSO‑d₆, 400 MHz) records the thiazole C4 proton as a singlet at δ 7.48 ppm, while the amine and hydrobromide protons exchange with residual water, appearing as a broad signal between δ 3.0–4.5 ppm. The ¹³C spectrum displays the C‑Br carbon at δ 102.4 ppm, consistent with the electronegative environment of the bromine substituent. Heavy metal limits comply with Ph.Eur. method 2.4.8, Category 2: arsenic ≤ 2 ppm, cadmium ≤ 1 ppm, lead ≤ 5 ppm, and mercury ≤ 1 ppm. Residual palladium, often of concern when this intermediate is sourced from Suzuki-coupling supply chains, is quantified by ICP-MS and restricted to <10 ppm.

Key purity attributes across standard commercial grades
Parameter	Technical Grade	Pharma Grade	Analytical Method
Assay (anhydrous basis)	≥ 98.0%	≥ 99.5%	HPLC (λ 254 nm)
Water (Karl Fischer)	≤ 0.5%	≤ 0.2%	KF coulometry
Residue on Ignition	≤ 0.1%	≤ 0.05%	Ph.Eur. 2.4.16
Free Bromide (ionic)	≤ 0.2%	≤ 0.05%	Argentometric titration
Related Substances (total)	≤ 1.0%	≤ 0.3%	HPLC area %

Logistics data: classified under Harmonized System code 2934.10 for compounds containing an unfused thiazole ring. The salt is packaged in 25 kg or 50 kg fiber drums with double low-density polyethylene liners; for air freight, 5 kg aluminium-laminate vacuum-sealed pouches mitigate humidity ingress at altitude. Storage stability testing per ICH Q1A (R2) at 40 °C/75% RH for 6 months revealed <0.1% increase in total related substances and no change in crystalline form by XRPD, confirming suitability for unrefrigerated warehousing in climate zone IV.

When Does the Hydrobromide Salt Offer Decisive Processing Advantages Over the Free Base?

The free base, 2-amino-5-bromothiazole, exhibits a melting point of 61–64 °C and a pronounced tendency to sublime during vacuum drying, leading to irregular weight loss in batch reactors and contamination of overhead lines. The hydrobromide salt eliminates this behavior entirely, as its ionic lattice requires >185 °C for any detectable mass transfer. In large-scale amination reactions—specifically Buchwald‑Hartwig couplings with aryl halides facilitated by Pd₂(dba)₃ (0.5–2 mol%) and Xantphos—the salt can be charged directly without pre-neutralization because the HBr counterion is scavenged by the inorganic base (typically Cs₂CO₃ or K₃PO₄, 2.5–3.0 equivalents) present in the coupling medium. In contrast, the free base demands storage under argon at –20 °C and pre-drying over molecular sieves to meet the moisture thresholds required for palladium catalyst longevity. Plant-scale observations in 500 L glass-lined reactors indicate that direct use of the hydrobromide salt reduces cycle time by approximately 45 min per batch by eliminating the neutralization and drying unit operations, while improving reproducibility of the catalyst induction period. A notable incompatibility exists with lithium amide bases: the salt cannot be employed directly in reactions requiring LDA or LiHMDS without prior liberation of the free amine, as the acidic proton of the hydrobromide quenches the strong base exothermically. For such lithium-mediated halogen-metal exchange or directed ortho-metalation sequences, a separate phase-transfer neutralization step (dichloromethane/saturated NaHCO₃) is mandatory.

Comparisons with Other 5-Halothiazole Intermediates in Cross-Coupling Efficiency

The bromine atom at the 5-position occupies a kinetic sweet spot for oxidative addition to low-valent palladium relative to the corresponding chloro and iodo analogs. 2-Amino-5-chlorothiazole (CAS 50382-20-2) requires more forceful conditions—typically Pd(OAc)₂ combined with 5 mol% of a trialkylphosphine ligand at 100–110 °C—to achieve meaningful conversion in Suzuki-Miyaura couplings with phenylboronic acid. The iodo derivative (CAS 91428-07-6) reacts rapidly even at 40 °C but is plagued by limited commercial availability, a cost premium exceeding 4× that of the bromide, and a propensity toward protodehalogenation side reactions under basic aqueous conditions. The bromothiazole thus provides a balance: oxidative addition proceeds with an activation barrier sufficiently low for turnover at 65–80 °C employing Pd(PPh₃)₄ or PdCl₂(dppf) at 1–2 mol%, yet the C–Br bond remains adequately stable during storage and handling. Comparative reaction calorimetry data from a published technical bulletin (Biotage Initiator+ microwave reactor, THF/H₂O 4:1, 1.5 eq of 4-methoxyphenylboronic acid, K₂CO₃ base) document 92% isolated yield of 2-amino-5-(4-methoxyphenyl)thiazole from the bromide in 20 min at 80 °C, versus 61% from the chloride under identical catalyst loading and extended reaction time (45 min). No published data for the iodide under these specific conditions was located. A secondary but critical differentiation relates to the 2-amino group’s protection strategy. With the bromine atom in place, the amine can be temporarily blocked as the acetamide or doubly protected as the phthalimide without triggering nucleophilic displacement of the halogen; this orthogonality is essential in the convergent synthesis of polyfunctional biaryl intermediates used in kinase inhibitor programs. Chloro derivatives occasionally show competitive displacement at elevated temperatures in the presence of strong nucleophiles, complicating impurity profiles.

Process Impurity Tracking During Pramipexole and Related Dopamine Agonist Production

The most documented industrial application of this hydrobromide salt is as the precursor to the aminothiazole fragment of pramipexole dihydrochloride monohydrate (CAS 191217-81-9). In the main synthetic sequence, 2-amino-5-bromothiazole hydrobromide undergoes a palladium-catalyzed Heck-type or carbonylative coupling to install the propyl side chain, followed by reduction and resolution. The salt form’s high purity directly influences the diastereomeric purity of the final API. One persistent process-related impurity, des‑bromo thiazole (2-aminothiazole, CAS 96-50-4), arises from hydrodebromination during hydrogenolysis steps and must be controlled below 0.10% in the penultimate intermediate. Using the hydrobromide salt with an initial des‑bromo content below 0.05% (as verified by HPLC) enables downstream chemists to maintain the critical impurity threshold without recourse to additional recrystallization. Equipment-specific failure mode: in stainless-steel (316L) hydrogenation autoclaves, prolonged contact of acidic hydrobromide salts with metal surfaces at 50 °C and 5 bar H₂ pressure can generate trace dissolved iron species that catalyze the hydrodebromination pathway. Facilities that substituted Hastelloy C‑22 in the reactor lining and installed a 0.5 µm post-filtration step reduced the des‑bromo impurity level by 0.04% absolute in validation batches. This illustrates that the salt’s intrinsic stability cannot be decoupled from plant metallurgy and operational parameters. The hydrobromide form also finds use in the synthesis of the 2-aminothiazole cores of the antirheumatic agent iguratimod (T‑614) and certain CSF‑1R inhibitors, where the bromine atom serves as a versatile handle for sequential derivatization—first via Negishi coupling to install an aryl zincate, then subsequent oxidation or sulfonylation at the 2-amino position. The free base, when substituted in these sequences, often required a protection/deprotection cycle that introduced 8–12% additional yield loss.

REACH and Hazard Communication Under CLP Regulation (EC) No 1272/2008

Classification: Acute Tox. 4 (H302 Harmful if swallowed), Skin Irrit. 2 (H315), Eye Irrit. 2 (H319), STOT SE 3 (H335). No specific environmental hazard classification has been assigned under current ECHA registered dossier data. The material must be handled in a fume hood rated for 0.5 m·s⁻¹ face velocity, and spill containment procedures adhere to local adsorption with vermiculite followed by disposal as halogenated organic waste (EWC code 16 05 08*). When neutralized with sodium hydroxide during waste treatment, the resulting free base precipitates as a filterable solid, facilitating recovery rather than incineration. A single-sentence note on supply chain: logistics providers must confirm that the material is not subject to Annex I of Regulation (EC) No 1005/2009 on ozone-depleting substances, nor listed in Annex III of the Rotterdam Convention; however, the bromide ion content necessitates compliance with local discharge limits for absorbable organic halides (AOX), typically 0.5 mg·L⁻¹ in EU member states.

Comparative profile of 2-amino-5-halothiazole intermediates
Feature	2-Amino-5-bromothiazole HBr	2-Amino-5-chlorothiazole	2-Amino-5-iodothiazole
Typical purity (HPLC)	99.5%	98.0%	97.0%
Suzuki coupling temp. window	65–80 °C	95–110 °C	35–50 °C
Relative cost factor (per mole)	1.0	0.7	4.2
Storage stability (ICH Q1A)	24 months	12 months	6 months
Protodehalogenation tendency	Low	Very low	Moderate

The absence of an acidic counterion in the chlorinated analog restrains its solubility in polar aprotic solvents like DMF and NMP, often necessitating mild heating to 50 °C for complete dissolution at 0.5 M concentration. The hydrobromide salt, by contrast, dissolves rapidly in DMF at 25 °C to a concentration of 1.2 M, a property exploited in continuous-flow setups employing perfluoroalkoxy (PFA) tubular reactors (1/8 in OD, 0.0625 in ID) where salt precipitation would cause blockages. In one published setup (Vapourtec R-series, residence time 15 min), the hydrobromide salt’s high solubility allowed a throughput of 12 mmol·h⁻¹ without back-pressure excursions beyond 2 bar. The 2-amino group’s nucleophilicity toward electrophilic reagents—when the counterion is bromide rather than chloride—displays a subtly modulated reactivity profile in reductive aminations with aliphatic ketones. The bromide anion’s polarizability is hypothesized to enhance solvation of the transition state in dichloromethane, though direct kinetic evidence from stopped-flow spectrometry is lacking. Published synthetic procedures nevertheless register an average 12% higher yield for the bromide salt relative to the chloride in the formation of N-cyclohexyl derivatives using sodium triacetoxyborohydride (1.4 eq) and acetic acid (0.5 eq) at 0 °C to room temperature over 18 h. Validation of the salt’s crystalline phase purity by powder X‑ray diffraction reveals a consistent pattern indexed to a triclinic unit cell (space group P-1) with no evidence of polymorphism across 12 consecutive production batches. This monomorphic character stands in contrast to the free base, which has been observed to form at least two distinct crystal habits depending on crystallization rate, complicating particle size distribution control during comminution.